NO343937B1 - Sammensetning som omfatter en fast dispersjon av minst 4{4-[3-(4-klor-3-trifluormetylfenyl)-ureido]-3-fluorfenoksy}-pyridin-2-karboksylsyremetylamid i hovedsakelig amorf form, dets solvater, hydrater, farmasøytisk akseptable salter eller en kombinasjon derav og en farmasøytisk akseptabel matriks som omfatter en farmasøytisk akseptabel polymer eller et sukker og/eller en sukker-alkohol og/eller syklodekstrin, en fremgangsmåte for fremstilling av den fast dispersjonen, og en farmasøytisk sammensetning derav for anvendelse ved behandling av hyperproliferative forstyrrelser slik som kreft - Google Patents
Sammensetning som omfatter en fast dispersjon av minst 4{4-[3-(4-klor-3-trifluormetylfenyl)-ureido]-3-fluorfenoksy}-pyridin-2-karboksylsyremetylamid i hovedsakelig amorf form, dets solvater, hydrater, farmasøytisk akseptable salter eller en kombinasjon derav og en farmasøytisk akseptabel matriks som omfatter en farmasøytisk akseptabel polymer eller et sukker og/eller en sukker-alkohol og/eller syklodekstrin, en fremgangsmåte for fremstilling av den fast dispersjonen, og en farmasøytisk sammensetning derav for anvendelse ved behandling av hyperproliferative forstyrrelser slik som kreftInfo
- Publication number
- NO343937B1 NO343937B1 NO20071584A NO20071584A NO343937B1 NO 343937 B1 NO343937 B1 NO 343937B1 NO 20071584 A NO20071584 A NO 20071584A NO 20071584 A NO20071584 A NO 20071584A NO 343937 B1 NO343937 B1 NO 343937B1
- Authority
- NO
- Norway
- Prior art keywords
- pharmaceutically acceptable
- solid dispersion
- sugar
- composition
- fluorophenoxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
- Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60475204P | 2004-08-27 | 2004-08-27 | |
PCT/US2005/030541 WO2006026500A1 (en) | 2004-08-27 | 2005-08-29 | New pharmaceutical compositions comprising 4-(4-(3-(4-chloro-3-trifluoromethyl-phenyl)-ureido)-3-fluoro-phenoxy)-pyridine-2-carboxylic acid for the treatment of hyper-proliferative disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20071584L NO20071584L (no) | 2007-05-24 |
NO343937B1 true NO343937B1 (no) | 2019-07-15 |
Family
ID=35517032
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20071584A NO343937B1 (no) | 2004-08-27 | 2007-03-26 | Sammensetning som omfatter en fast dispersjon av minst 4{4-[3-(4-klor-3-trifluormetylfenyl)-ureido]-3-fluorfenoksy}-pyridin-2-karboksylsyremetylamid i hovedsakelig amorf form, dets solvater, hydrater, farmasøytisk akseptable salter eller en kombinasjon derav og en farmasøytisk akseptabel matriks som omfatter en farmasøytisk akseptabel polymer eller et sukker og/eller en sukker-alkohol og/eller syklodekstrin, en fremgangsmåte for fremstilling av den fast dispersjonen, og en farmasøytisk sammensetning derav for anvendelse ved behandling av hyperproliferative forstyrrelser slik som kreft |
NO2019033C NO2019033I1 (no) | 2004-08-27 | 2019-08-05 | regorafenib |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO2019033C NO2019033I1 (no) | 2004-08-27 | 2019-08-05 | regorafenib |
Country Status (41)
Country | Link |
---|---|
US (2) | US20060058358A1 (no) |
EP (2) | EP2589384A1 (no) |
JP (1) | JP5017115B2 (no) |
KR (1) | KR101336737B1 (no) |
CN (2) | CN102885813A (no) |
AR (1) | AR050616A1 (no) |
AU (1) | AU2005279996A1 (no) |
BR (1) | BRPI0514715B1 (no) |
CA (1) | CA2578438C (no) |
CL (1) | CL2010001484A1 (no) |
CR (1) | CR8980A (no) |
CY (1) | CY2017038I2 (no) |
DK (1) | DK1793824T3 (no) |
EA (1) | EA010832B1 (no) |
EC (1) | ECSP077299A (no) |
ES (1) | ES2561618T3 (no) |
GT (1) | GT200500230A (no) |
HN (1) | HN2005000484A (no) |
HR (1) | HRP20160156T1 (no) |
HU (2) | HUE026654T2 (no) |
IL (1) | IL181590A (no) |
LT (1) | LTC1793824I2 (no) |
LU (1) | LUC00047I2 (no) |
MA (1) | MA28911B1 (no) |
ME (2) | MEP35808A (no) |
MX (1) | MX2007002397A (no) |
MY (1) | MY191349A (no) |
NI (1) | NI200700064A (no) |
NO (2) | NO343937B1 (no) |
NZ (1) | NZ553557A (no) |
PE (2) | PE20060505A1 (no) |
PL (1) | PL1793824T3 (no) |
PT (1) | PT1793824E (no) |
RS (1) | RS54580B1 (no) |
SI (1) | SI1793824T1 (no) |
TN (1) | TNSN07076A1 (no) |
TW (1) | TWI369987B (no) |
UA (1) | UA92472C2 (no) |
UY (1) | UY29086A1 (no) |
WO (1) | WO2006026500A1 (no) |
ZA (1) | ZA200702392B (no) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
ATE556713T1 (de) * | 1999-01-13 | 2012-05-15 | Bayer Healthcare Llc | Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer |
US7371763B2 (en) * | 2001-04-20 | 2008-05-13 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
MY169670A (en) | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
US20080108672A1 (en) * | 2002-01-11 | 2008-05-08 | Bernd Riedl | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors |
AU2003209116A1 (en) * | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Aryl ureas with angiogenesis inhibiting activity |
US7557129B2 (en) * | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
PT1636585E (pt) * | 2003-05-20 | 2008-03-27 | Bayer Pharmaceuticals Corp | Diarilureias com actividade inibidora de cinase |
JP4777887B2 (ja) * | 2003-07-23 | 2011-09-21 | バイエル、ファーマシューテイカルズ、コーポレイション | 病気および状態の処置および防止のためのフロロ置換オメガカルボキシアリールジフェニル尿素 |
NZ553804A (en) * | 2004-09-29 | 2010-07-30 | Bayer Schering Pharma Ag | Thermodynamically stable form of bay 43-9006 tosylate |
EP1868579B1 (en) * | 2005-03-07 | 2010-09-29 | Bayer Schering Pharma Aktiengesellschaft | Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
US20090074917A2 (en) * | 2006-07-26 | 2009-03-19 | Remington Direct Lp | Low-calorie, no laxation bulking system |
US20080026038A1 (en) * | 2006-07-26 | 2008-01-31 | Remington Direct Lp | No laxation, low flatulence bulking system |
JP2010505962A (ja) | 2006-10-09 | 2010-02-25 | 武田薬品工業株式会社 | キナーゼ阻害剤 |
AR062927A1 (es) * | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
EP2089003A1 (en) * | 2006-11-09 | 2009-08-19 | Abbott GmbH & Co. KG | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
EP1920767A1 (en) * | 2006-11-09 | 2008-05-14 | Abbott GmbH & Co. KG | Melt-processed imatinib dosage form |
AR065720A1 (es) | 2007-03-14 | 2009-06-24 | Tibotec Pharm Ltd | Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso. |
WO2008138755A2 (en) * | 2007-05-11 | 2008-11-20 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions for poorly soluble drugs |
WO2009114703A2 (en) * | 2008-03-12 | 2009-09-17 | Fox Chase Cancer Center | Combination therapy for the treatment of cancer |
UA107186C2 (xx) * | 2008-12-03 | 2014-12-10 | Тверді форми дозування бендамустину | |
WO2010068951A1 (en) * | 2008-12-12 | 2010-06-17 | Fox Chase Cancer Center | Combination therapy based on src and aurora kinase inhibition for the treatment of cancer |
JO3112B1 (ar) * | 2010-03-29 | 2017-09-20 | Ferring Bv | تركيبة دوائية سريعة التحلل |
AR081060A1 (es) * | 2010-04-15 | 2012-06-06 | Bayer Schering Pharma Ag | Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida |
RU2566716C2 (ru) * | 2010-06-09 | 2015-10-27 | Эббви Бахамаз Лтд. | Твердые дисперсии, содержащие ингибиторы киназ |
MY165086A (en) | 2010-07-12 | 2018-02-28 | Salix Pharmaceuticals Ltd | Formulations of rifaximin and uses thereof |
EP2595628A1 (en) | 2010-07-19 | 2013-05-29 | Bayer HealthCare LLC | Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
US9381177B2 (en) | 2010-10-01 | 2016-07-05 | Bayer Intellectual Property Gmbh | Substituted N-(2-arylamino)aryl sulfonamide-containing combinations |
UA113500C2 (xx) * | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
CA2811805A1 (en) | 2010-10-29 | 2012-05-03 | Abbvie Inc. | Solid dispersions containing an apoptosis-inducing agent |
CN103301066B (zh) * | 2012-03-15 | 2018-12-07 | 苏州泽璟生物制药有限公司 | 一种改善吸收性能的固体分散体及其制备 |
AR092439A1 (es) * | 2012-09-06 | 2015-04-22 | Bayer Healthcare Llc | Composicion farmaceutica recubierta que contiene regorafenib |
US9211290B2 (en) * | 2012-12-31 | 2015-12-15 | Noven Therapeutics, Llc | Solid dispersions of amorphous paroxetine mesylate |
US9518020B2 (en) | 2013-10-04 | 2016-12-13 | Hetero Research Foundation | Process for Regorafenib |
CN104721142B (zh) * | 2013-12-18 | 2020-04-28 | 山东新时代药业有限公司 | 一种利伐沙班固体分散体及其制备方法 |
US9790185B2 (en) | 2014-07-09 | 2017-10-17 | Shilpa Medicare Limited | Process for the preparation of regorafenib and its crystalline forms |
CN105267167A (zh) * | 2015-09-11 | 2016-01-27 | 江苏嘉逸医药有限公司 | 一种瑞戈非尼口服固体药物组合物的制备方法 |
CN105330600B (zh) * | 2015-11-30 | 2018-05-22 | 山东罗欣药业集团股份有限公司 | 一种瑞戈菲尼的制备方法 |
CN105879049B (zh) * | 2016-05-13 | 2019-03-26 | 浙江大学 | 一种瑞戈非尼与β-环糊精的包合物及其制备方法 |
CN107661296A (zh) * | 2016-07-27 | 2018-02-06 | 江苏先声药业有限公司 | 一种瑞戈非尼固体分散体及其制备方法 |
PT3518924T (pt) | 2016-09-30 | 2022-10-27 | Salix Pharmaceuticals Inc | Formas de dispersão sólidas de rifaximina |
CN111166724A (zh) * | 2018-11-09 | 2020-05-19 | 北京化工大学 | 一种瑞戈非尼纳米分散体、片剂及其制备方法 |
EP3861989A1 (en) | 2020-02-07 | 2021-08-11 | Bayer Aktiengesellschaft | Pharmaceutical composition containing regorafenib and a stabilizing agent |
CN112587485A (zh) * | 2021-01-08 | 2021-04-02 | 湖南南新制药股份有限公司 | 一种药物固体分散体及其制备方法 |
CN112842998A (zh) * | 2021-01-19 | 2021-05-28 | 深圳市简一生物科技有限公司 | 一种瑞戈非尼分散剂及其制备方法 |
FR3123358B1 (fr) * | 2021-05-25 | 2024-05-10 | Vecormat Bfc | Procédé d’élaboration d’un matériau naturel composite à faible emprunte carbone et fort taux de matière naturelle. |
WO2022253945A1 (en) | 2021-06-04 | 2022-12-08 | Bayer Aktiengesellschaft | Pharmaceutical dosage forms comprising 3-(5-methyl-1,3-thiazol-2-yl)-5-[(3r)-tetrahydrofuran-3-yloxy]-n-{(1r)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}-benzamide |
CN114767633B (zh) * | 2022-04-07 | 2023-03-31 | 郑州大学第一附属医院 | 含抗乳腺癌药物他莫昔芬的固体分散体、制备方法及制剂 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000042012A1 (en) * | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS |
WO2000041698A1 (en) * | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
WO2003068228A1 (en) * | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Aryl ureas with angiogenesis inhibiting activity |
WO2005009961A2 (en) * | 2003-07-23 | 2005-02-03 | Bayer Pharmaceuticals Corporation | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4151273A (en) * | 1974-10-31 | 1979-04-24 | The Regents Of The University Of California | Increasing the absorption rate of insoluble drugs |
US4220302A (en) | 1978-07-21 | 1980-09-02 | Hampton Diane M | Nursing bottle holder |
ATE159426T1 (de) * | 1991-04-16 | 1997-11-15 | Nippon Shinyaku Co Ltd | Verfahren zur herstellung einer festen dispersion |
UA67763C2 (uk) * | 1997-12-22 | 2004-07-15 | Байер Фармасьютікалс Корпорейшн | Арил- та гетероарилзаміщені гетероциклічні похідні сечовини, фармацевтична композиція та спосіб лікування захворювання, спричиненого кіназою raf |
CN1213022C (zh) * | 1997-12-22 | 2005-08-03 | 拜尔有限公司 | 用对称和不对称的取代二苯脲抑制raf激酶 |
TR200002618T2 (tr) * | 1997-12-22 | 2001-04-20 | Bayer Corporation | Sübstitüe edilmiş heterosiklik üreler kullanılarak raf kinazın inhibe edilmesi |
US7928239B2 (en) | 1999-01-13 | 2011-04-19 | Bayer Healthcare Llc | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas |
KR101091101B1 (ko) * | 1999-01-13 | 2011-12-09 | 바이엘 헬스케어 엘엘씨 | raf 키나아제 저해제로서의 ω-카르복시아릴 치환 디페닐 우레아 |
JP3789066B2 (ja) | 1999-12-08 | 2006-06-21 | 三菱電機株式会社 | 液晶表示装置 |
JPWO2001078716A1 (ja) * | 2000-04-19 | 2004-07-22 | 藤沢薬品工業株式会社 | 吸収性が改善された固体分散体 |
US8725620B2 (en) | 2000-07-10 | 2014-05-13 | Nobuyoshi Morimoto | System and method for negotiating improved terms for products and services being purchased through the internet |
WO2002013792A1 (fr) * | 2000-08-11 | 2002-02-21 | Eisai Co., Ltd. | Dispersion solide médicamenteuse à solubilité accrue |
WO2002048141A1 (en) | 2000-12-11 | 2002-06-20 | Takeda Chemical Industries, Ltd. | Medicinal compositions improved in solublity in water |
US7235576B1 (en) * | 2001-01-12 | 2007-06-26 | Bayer Pharmaceuticals Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
WO2002064121A1 (en) * | 2001-02-13 | 2002-08-22 | Astrazeneca Ab | Novel modified released formulation |
SE0103838D0 (sv) * | 2001-11-16 | 2001-11-16 | Astrazeneca Ab | Pharmaceutical formulation & product |
AU2002365899B2 (en) * | 2001-12-04 | 2007-09-13 | Onyx Pharmaceuticals, Inc. | RAF-MEK-ERK pathway inhibitors to treat cancer |
US20030207872A1 (en) * | 2002-01-11 | 2003-11-06 | Bayer Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
RU2004123621A (ru) * | 2002-02-01 | 2005-04-10 | Пфайзер Продактс Инк. (Us) | Лекарственные формы с немедленным высвобождением, содержащие твердые дисперсии лекарств |
CA2430180C (en) | 2003-05-21 | 2010-03-16 | Royal Group Technologies Limited | Cascade shade |
JP5128948B2 (ja) * | 2004-08-27 | 2013-01-23 | ニッポネックス インコーポレイテッド | 癌の治療のための新規な薬剤組成物 |
-
2005
- 2005-08-25 MY MYPI20054000A patent/MY191349A/en unknown
- 2005-08-26 HN HN2005000484A patent/HN2005000484A/es unknown
- 2005-08-26 US US11/212,109 patent/US20060058358A1/en not_active Abandoned
- 2005-08-26 UY UY29086A patent/UY29086A1/es not_active Application Discontinuation
- 2005-08-26 AR ARP050103568A patent/AR050616A1/es not_active Application Discontinuation
- 2005-08-26 PE PE2005000984A patent/PE20060505A1/es active IP Right Grant
- 2005-08-26 TW TW094129395A patent/TWI369987B/zh active
- 2005-08-26 PE PE2010000029A patent/PE20100432A1/es active IP Right Grant
- 2005-08-26 GT GT200500230A patent/GT200500230A/es unknown
- 2005-08-29 RS RS20160039A patent/RS54580B1/en unknown
- 2005-08-29 PT PT57924862T patent/PT1793824E/pt unknown
- 2005-08-29 JP JP2007533489A patent/JP5017115B2/ja active Active
- 2005-08-29 PL PL05792486T patent/PL1793824T3/pl unknown
- 2005-08-29 ME MEP-358/08A patent/MEP35808A/xx unknown
- 2005-08-29 CN CN2012102807209A patent/CN102885813A/zh active Pending
- 2005-08-29 SI SI200532037T patent/SI1793824T1/sl unknown
- 2005-08-29 CN CNA2005800371513A patent/CN101287463A/zh active Pending
- 2005-08-29 NZ NZ553557A patent/NZ553557A/en unknown
- 2005-08-29 BR BRPI0514715-8A patent/BRPI0514715B1/pt active IP Right Grant
- 2005-08-29 CA CA2578438A patent/CA2578438C/en active Active
- 2005-08-29 AU AU2005279996A patent/AU2005279996A1/en not_active Abandoned
- 2005-08-29 ME MEP-2008-358A patent/ME00152B/me unknown
- 2005-08-29 KR KR1020077006801A patent/KR101336737B1/ko active IP Right Review Request
- 2005-08-29 DK DK05792486.2T patent/DK1793824T3/en active
- 2005-08-29 EA EA200700501A patent/EA010832B1/ru unknown
- 2005-08-29 UA UAA200703203A patent/UA92472C2/ru unknown
- 2005-08-29 ES ES05792486.2T patent/ES2561618T3/es active Active
- 2005-08-29 MX MX2007002397A patent/MX2007002397A/es active IP Right Grant
- 2005-08-29 EP EP13151040.6A patent/EP2589384A1/en not_active Withdrawn
- 2005-08-29 EP EP05792486.2A patent/EP1793824B1/en not_active Revoked
- 2005-08-29 WO PCT/US2005/030541 patent/WO2006026500A1/en active Application Filing
- 2005-08-29 HU HUE05792486A patent/HUE026654T2/en unknown
-
2007
- 2007-02-26 TN TNP2007000076A patent/TNSN07076A1/en unknown
- 2007-02-27 NI NI200700064A patent/NI200700064A/es unknown
- 2007-02-27 IL IL181590A patent/IL181590A/en active IP Right Grant
- 2007-03-05 EC EC2007007299A patent/ECSP077299A/es unknown
- 2007-03-07 CR CR8980A patent/CR8980A/es unknown
- 2007-03-22 MA MA29767A patent/MA28911B1/fr unknown
- 2007-03-22 ZA ZA200702392A patent/ZA200702392B/xx unknown
- 2007-03-26 NO NO20071584A patent/NO343937B1/no active Protection Beyond IP Right Term
-
2010
- 2010-12-20 CL CL2010001484A patent/CL2010001484A1/es unknown
-
2016
- 2016-02-12 HR HRP20160156TT patent/HRP20160156T1/hr unknown
- 2016-03-22 LT LTPA2016008C patent/LTC1793824I2/lt unknown
-
2017
- 2017-01-27 US US15/417,469 patent/US20170165243A1/en not_active Abandoned
- 2017-11-08 LU LU00047C patent/LUC00047I2/fr unknown
- 2017-11-09 CY CY2017038C patent/CY2017038I2/el unknown
- 2017-11-21 HU HUS1700047C patent/HUS1700047I1/hu unknown
-
2019
- 2019-08-05 NO NO2019033C patent/NO2019033I1/no unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000042012A1 (en) * | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS |
WO2000041698A1 (en) * | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
WO2003068228A1 (en) * | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Aryl ureas with angiogenesis inhibiting activity |
WO2005009961A2 (en) * | 2003-07-23 | 2005-02-03 | Bayer Pharmaceuticals Corporation | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
NO20060870L (no) * | 2003-07-23 | 2006-04-07 | Bayer Pharmaceuticals Corp | Fluorsubstituert omega-karboksyaryldifenylurea for behandling og profylakse av sykdommer og tilstander |
Non-Patent Citations (2)
Title |
---|
AHMAD TANYA ET AL, "Kinase inhibition with BAY 43-9006 in renal cell carcinoma.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. 15 SEP 2004, Presentation at First International Conference on Innovations and Challenges in Renal Cancer, Cambridge, Massachusetts, (20040319), vol. 10, no. 18 Pt 2, ISSN 1078-0432, pages 6388S - 6392S, , Dated: 01.01.0001 * |
LEUNER C ET AL, "Improving drug solubility for oral delivery using solid dispersions", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, (20000703), vol. 50, no. 1, ISSN 0939-6411, pages 47 - 60, Dated: 01.01.0001 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO343937B1 (no) | Sammensetning som omfatter en fast dispersjon av minst 4{4-[3-(4-klor-3-trifluormetylfenyl)-ureido]-3-fluorfenoksy}-pyridin-2-karboksylsyremetylamid i hovedsakelig amorf form, dets solvater, hydrater, farmasøytisk akseptable salter eller en kombinasjon derav og en farmasøytisk akseptabel matriks som omfatter en farmasøytisk akseptabel polymer eller et sukker og/eller en sukker-alkohol og/eller syklodekstrin, en fremgangsmåte for fremstilling av den fast dispersjonen, og en farmasøytisk sammensetning derav for anvendelse ved behandling av hyperproliferative forstyrrelser slik som kreft | |
HRP20190660T1 (hr) | FORMULACIJA N-[2,4-bis(1,1-DIMETILETIL)-5-HIDROKSIFENIL]-1,4-DIHIDRO-4-OKSOHINOLIN-3-KARBOKSAMIDA U OBLIKU TABLETE ZA UPOTREBU U TRETMANU CISTIČNE FIBROZE | |
AR054234A1 (es) | Composicion farmaceutica para el tratamiento del cancer | |
CA2795804C (en) | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof | |
BRPI0612188B8 (pt) | preparação farmacêutica para aplicação oral, método para a produção de uma preparação farmacêutica oral, preparação de comprimido para aplicação oral, método para a produção de uma preparação de comprimido | |
NO20090328L (no) | Nye forbindelser 385 | |
NO20045103L (no) | Benzofuserte heteroarylamid-derivater av thienopyridiner anvendelige som terapeutiske midler, farmasoytiske blandinger omfattende de samme og fremgangsmater for deres anvendelse | |
NZ592719A (en) | PHARMACEUTICAL FORMULATION 514 comprising 4-[3-( 4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one | |
WO2007033231A3 (en) | Novel lysine salts of 4-((phenoxyalkyl) thio)-phenoxyacetic acid derivatives | |
IL151791A (en) | Use of a dry powder containing glycopyrulate micro-particles for the preparation of a pharmaceutical preparation for the treatment of respiratory diseases | |
RS55464B1 (sr) | 2-[4-(3- i 2 fluorbenziloksi) benzilamino] propanamidi visokog stepena čistoće za upotrebu kao lekovi i farmaceutski preparati koji ih sadrže | |
NO20084853L (no) | Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni | |
NO20092527L (no) | Prolegemidler, fremgangsmate for fremstilling og anvendelse derav | |
WO2004072031A3 (en) | Phenylacetamides and their use as glucokinase modulators | |
SG10201407947WA (en) | Compressible-coated pharmaceutical compositions and tablets and methods of manufacture | |
BRPI0912842A8 (pt) | composição farmacêutica, métodos para prevenir ou tratar o rubor induzido por niacina em um indivíduo, para reduzir pelo menos um sintoma de rubor relacionado com a terapia com niacina em um indivíduo, para diminuir os efeitos colaterais relacionados com a protaglandina em um indivíduo, para diminuir uma taxa de descontinuação do tratamento com niacina por um indivíduo, para aumentar a submissão do paciente ao tratamento com niacina, para tratar aterosclerose em um paciente, para tratar uma doença relacionada com um perfil de hdl baixo em um paciente, formulação do ácido nicotínico de dispensação modificada, uso da composição farmacêutica, e, microcápsula de aspirina | |
BRPI0417186A (pt) | método de tratamento de um indivìduo tendo uma hemoglobinopatia ou uma anemia, de modulação da diferenciação de uma célula-tronco ou precursora de cd34+ para uma linhagem de eritróides, e, composição farmacêutica | |
EP2279727A3 (en) | Nanoparticulate aripiprazole formulations | |
WO2008148967A3 (fr) | Preparations pharmaceutiques ou cosmetiques pour application topique et/ou parenterale, leurs procedes de preparation, et leurs utilisations | |
NO20055367L (no) | Kombinasjoner som innbefatter paroksetin og 2-(S)-4-fluor-2-metyl-fenyl)-piperazin-1-karboksylsyer (1-(R)-(3,5-bis-trifluor-2-metyl-fenyl)-etyl]metylamid for behandling av depresjon og/eller angst | |
SE9904413D0 (sv) | Comminuted form | |
JP2022082697A (ja) | 眼科組成物 | |
DE602006008186D1 (de) | Neues imprägnierverfahren einer textiloberfläche | |
IL187575A (en) | Benzofuranyl derivatives ,pharmaceutical formulations comprising the same and use thereof in the preparation of medicaments for the treatment of 5-ht6-receptor related disorders | |
WO2007070355A3 (en) | Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
SPCF | Filing of supplementary protection certificate |
Free format text: PRODUCT NAME: REGORAFENIB; REG. NO/DATE: EU/1/13/858/001-002 20130909 Spc suppl protection certif: 2019033 Filing date: 20190805 |
|
CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: BAYER HEALTHCARE LLC, US |
|
SPCS | Change of name or address of the owner of a supplementary protection certificate |
Owner name: BAYER HEALTHCARE LLC, US Spc suppl protection certif: 2019033 |
|
SPCG | Granted supplementary protection certificate |
Free format text: PRODUCT NAME: REGORAFENIB; REG. NO/DATE: EU/1/13/858/001-002 20130909 Spc suppl protection certif: 2019033 Filing date: 20190805 Extension date: 20280829 |